title: Emerging treatment of atopic dermatitis.
abstract: Atopic dermatitis is a chronically relapsing eczematous disease of the skin. A wide range of therapeutic regimens has been used for atopic dermatitis. A better understanding of its pathogenesis will also lead to the development of novel approaches to treating this disease. This article reviews the recent advances in allergen-specific sublingual immunotherapy and therapy with antileukotriene drugs, probiotics, mycophenolate mofetil, leflunomide, and intermittent fluticasone propionate ointment, which the authors expect will be clinically useful therapies in the near future.
authors.affiliation: Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China.
authors.forename: Chih-Jung
authors.initials: CJ
authors.lastname: Hsu
authors.forename: Li-Fang
authors.initials: LF
authors.lastname: Wang
mesh_terms: D000730:Androstadienes / Q000276:immunology / Q000627:therapeutic use; D000818:Animals; D003876:Dermatitis, Atopic / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000379:methods / Q000639:trends; D000068298:Fluticasone; D006634:Histamine H1 Antagonists / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D020024:Leukotriene Antagonists / Q000276:immunology / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D000730:Androstadienes; D006634:Histamine H1 Antagonists; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D020024:Leukotriene Antagonists; D000068298:Fluticasone; D000077339:Leflunomide; D009173:Mycophenolic Acid